We aimed to compare apparent steady-state oral clearance (CL/F) of the antiepileptic drug levetiracetam (LEV) in elderly (66-80 years, n=105) and very elderly (81-96 years, n=70) vs nonelderly (30-65 years, n=97) patients with epilepsy. Median weight-normalized CL/F (mLmin(-1)kg(-1)) decreased from 1.23 (nonelderly) to 0.83 (elderly) and 0.59 (very elderly) (p<0.001). LEV CL/F significantly declines with aging, elderly and very elderly patients requiring an about 30% and 50% lower dose, respectively, compared to nonelderly adults to achieve a given LEV plasma concentration.
Contin M., Mohamed S., Albani F., | Riva R., Baruzzi A. (2012). Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. EPILEPSY RESEARCH, 98, 130-134 [10.1016/j.eplepsyres.2011.08.020].
Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy
CONTIN, MANUELA MARIA ANTONIA;MOHAMED, SUSAN;ALBANI, FIORENZO;RIVA, ROBERTO;BARUZZI, AGOSTINO
2012
Abstract
We aimed to compare apparent steady-state oral clearance (CL/F) of the antiepileptic drug levetiracetam (LEV) in elderly (66-80 years, n=105) and very elderly (81-96 years, n=70) vs nonelderly (30-65 years, n=97) patients with epilepsy. Median weight-normalized CL/F (mLmin(-1)kg(-1)) decreased from 1.23 (nonelderly) to 0.83 (elderly) and 0.59 (very elderly) (p<0.001). LEV CL/F significantly declines with aging, elderly and very elderly patients requiring an about 30% and 50% lower dose, respectively, compared to nonelderly adults to achieve a given LEV plasma concentration.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
